



Novo Nordisk Ireland Limited: Coronavirus (Covid-19) and the supply of Novo Nordisk medicinal products in Ireland

Dublin, Ireland, 26 March 2020 - In light of the current situation with the coronavirus (Covid-19) outbreak and queries regarding the supply of medicinal products in Ireland, Novo Nordisk wish to reassure healthcare professionals and patients that **Novo Nordisk is currently able to supply all products to the Irish market.**

In line with guidance from the Health Products Regulatory Authority (HPRA), the Pharmaceutical Society of Ireland (PSI) and the Health Service Executive (HSE), **Novo Nordisk strongly recommend that patients request and are dispensed only one month's medication at this time.**

This action is necessary to prevent stockpiling of medicines which may ultimately lead to stock shortages. It will also ensure that all patients have access to the medicines they need.

We also wish to reiterate that Novo Nordisk closely monitors stock levels and logistic operations to ensure continuity of supply and this will continue during the Covid-19 outbreak. **Any problems that pharmacists or patients appear to be experiencing currently with sourcing stock are expected to be very transient and due entirely to the movement of stock through the supply chain.**

We appreciate that you may have queries and concerns regarding the supply of medicines for you or for your patients and we advise you to contact us on 1850 665 665 to discuss further.

About Novo Nordisk

Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 42,700 people in 80 countries and markets its products in more than 170 countries. For more information, visit novonordisk.com, [Facebook](#), [Twitter](#), [LinkedIn](#), [YouTube](#)

IE20NNG00006; Date of preparation: March 2020

The Apis bull logo is a registered trademark owned by Novo Nordisk A/S

Directors: Matt Regan (Irish), Mads Veggerby Lausten (Danish), Tomas Haagen (Danish). General Manager: Owen Treacy (Irish)

Novo Nordisk Ltd.	First Floor, Block A The Crescent Building Northwood Business Park Santry, Dublin 9 D09 X8W3 Ireland	Telephone: +353 1 8629700 Telefax: +353 1 8629 725	E-mail: infoireland@novonordisk.com Internet: www.novonordisk.ie	Reg. No.: 61378 VAT No.: 4510223A
--------------------------	---	---	---	--
